Answers are grounded in this paper and cite their sources.
Integrated review explores rubusoside’s biosynthesis and bioactive properties, indicating its health potential.
Growing concerns over sugar-related metabolic disorders have intensified interest in natural sweeteners that combine desirable sensory attributes with health-promoting functions. Rubusoside (RUB), a tetracyclic diterpene glycoside mainly derived from Rubus suavissimus S. Lee, has emerged as a promising candidate because of its high sweetness, minimal caloric contribution, and improved taste profile relative to stevioside. Beyond its conventional role as a sweetener, RUB has demonstrated multiple biofunctional properties, highlighting its potential as both a food ingredient and a bioactive compound. Although studies on RUB have expanded in recent years, the available evidence remains dispersed across chemistry, biosynthesis, pharmacology, and application-oriented research. A comprehensive synthesis is therefore warranted to clarify current knowledge, identify critical gaps, and support future translational development. In this review, we integrate recent progress in the physicochemical properties, production strategies, pharmacological activities, and mechanistic basis of RUB, with particular emphasis on developments that may facilitate its broader utilization. Special attention is paid to the evolution of manufacturing approaches from traditional extraction to enzymatic conversion and de novo biosynthesis in engineered yeast, which may improve production efficiency and sustainability. We further highlight the emerging multifunctionality of RUB, including its application as a natural solubilizer and its anti-cariogenic, metabolic regulatory, anti-inflammatory, antioxidant, and neuroprotective activities. By connecting advances in production technology with evidence of biological efficacy and application potential, this review offers a more integrated framework for understanding RUB and provides guidance for future studies on pharmacokinetics, tissue distribution, regulatory evaluation, and product development.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: